FDA Approves Jideytro (zidesamtinib) for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer
RegulatoryapprovedJideytroPositive
AI Analysis
Summary
GSK announced FDA approval of Jideytro (zidesamtinib), a ROS1 selective inhibitor, for treating adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. This represents a regulatory milestone approval for the company's targeted cancer therapy.
Outcome Details
FDA approval for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer
Importance:8/10
Sentiment:
0.95
FDA approvalOncologyLung cancerROS1 inhibitor
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on July 22, 2026 8:07 PM